FIELD: biotechnology.
SUBSTANCE: chimeric fusion protein containing a targeting moiety for cancer cell targeting, an immunomodulating moiety that counteracts the immune tolerance of cancer cells, and an amino acid spacer is prepared recombinantly.
EFFECT: invention allows to increase the effectiveness of cancer diseases treatment.
9 cl, 65 dwg, 1 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED IMMUNOMODULATORY PROTEINS AND METHODS FOR PRODUCTION THEREOF | 2014 |
|
RU2698975C2 |
| FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME | 2014 |
|
RU2662991C2 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| VACCINE COMPOSITION AND USE THEREOF | 2016 |
|
RU2726411C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX CONTAINING A CELL-PENETRATING PEPTIDE, A CARGO MOLECULE, AND A TLR PEPTIDE AGONIST, FOR APPLICATION IN MEDICINE | 2017 |
|
RU2769314C1 |
| BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING CD137 AND TUMOR ANTIGENS AND VARIANTS OF THEIR APPLICATION | 2018 |
|
RU2805648C2 |
| FUSED POLYPEPTIDE WITH ANTICANCER ACTIVITY | 2016 |
|
RU2727165C2 |
| COMBINATION OF IMMUNE CHECKPOINT MODULATOR AND COMPLEX CONTAINING CELL-PENETRATING PEPTIDE, CARGO MOLECULE, AND TLR PEPTIDE AGONIST FOR MEDICAL USE | 2017 |
|
RU2748378C2 |
| NK-CELL ACTIVATING FUSED PROTEIN, NK-CELLS AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2018 |
|
RU2740438C1 |
